Delving into the Latest Updates on D-0011 with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

long-acting dual PDGF/VEGF antagonist(Chengdu Easton Biopharmaceuticals)

Target

PDGF x VEGF

Action

inhibitors

Mechanism

PDGF inhibitors(Platelet-derived growth factor inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Chengdu Easton Biopharmaceuticals Co., Ltd.

Active Organization

Chengdu Easton Biopharmaceuticals Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

The ability of defective-interfering (DI) particles of vesicular stomatitis virus (VSV) to induce interferon was studied in relation to the amount of rapidly reannealling (snapback) [±] double-stranded sequences in their RNA.Five DI particles propagated in BHK-21 cells were analyzed: 2 DI particles generated by undiluted passages of cloned wild-type VSV (Indiana); 2 DI particles generated by serial undiluted passages of culture fluid from L cells persistently infected with VSV; and D0-011, a DI particle with [±] snapback RNA, which is known to be a potent inducer of interferon.Induction of interferon in L cells by these DI particles was not proportional to the amount of [±] sequences in their RNA.DI-011 (26-37% [±] RNA sequences) induced a signficant amount of interferon at a multiplicity of infection of 1 DI particle per cell.In contrast, the 2 DI particles from wild-type VSV (43-54% [±] RNA sequences) were 20- to 30-fold less efficient inducers of interferon than DI-011.Furthermore, the 2 DI particles (1-4% [±] RNA sequences) generated from L cell carrier cultures were only slightly less efficient inducers of interferon than the wild-type DI particles.Apparently, a population of DI particles which contains [±] RNA is not selected in L cells persistently infected with VSV.

100 Deals associated with D-0011

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Discovery	China	Chengdu Easton Biopharmaceuticals Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data